



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Date: 29<sup>th</sup> October 2018**

To  
National Stock Exchange of India Limited &  
BSE Limited.  
Scrip Code: NSE- GRANULES; BSE-532482.

**Sub: Outcome of 187<sup>th</sup> Board meeting dated 29<sup>th</sup> October, 2018.**  
**Ref: Regulation 30 and 33 of the Listing Regulations.**

Dear Sir,

The Board of Directors at their meeting has -

1. Approved the Un-Audited financial results (Standalone & Consolidated) for the second quarter ended 30<sup>th</sup> September, 2018 prepared under Indian Accounting Standards (Ind - AS);
2. Declared second interim dividend of 25 paise per share of face value of Re. 1/- each representing 25% of paid-up capital for the financial year 2018-19;
3. Fixed the record date as 10<sup>th</sup> November 2018 for the purpose of payment of second interim dividend for the financial year 2018-19.
4. Appointed Mr. Arun Sawhney as an Additional Director, categorized as Independent, on the Board of the Company with immediate effect and his appointment is subject to approval of the shareholders.

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing the Un-Audited financial results (Standalone and Consolidated) of the Company for the first quarter ended 30<sup>th</sup> June, 2018.

We also enclose a copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations and press release.

The meeting of the Board of Directors of the Company commenced at 4.00 P.M and concluded at 5.45 P.M.

Request you to take the above information on record.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

  


**CHAITANYA TUMMALA**  
**(COMPANY SECRETARY &**  
**COMPLIANCE OFFICER)**

Encl: As above

# B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City  
Orwell, 6th Floor, Unit-3  
Sy. No. 83/1, Plot No. 2, Raidurg  
Hyderabad-500081, India

Telephone : +91 40 7182 2000  
Fax : +91 40 7182 2399

## Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results pursuant to Regulation 33 of the Listing Regulations

To

The Board of Directors of Granules India Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('Statement') of Granules India Limited ('the Company'), its subsidiaries, joint venture and associate listed in Annexure - I (collectively "the Group") for the quarter ended 30 September 2018 and year-to-date results for the period from 1 April 2018 to 30 September 2018 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these consolidated financial results based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We did not review the financial information of the two subsidiaries, incorporated outside India, included in the Statement of unaudited quarterly consolidated financial results and consolidated year-to-date financial results, whose unaudited financial information reflect total assets of INR 69,851.66 lakhs as at 30 September 2018, total revenue of INR 15,966.05 lakhs and INR 25,534.22 lakhs for the quarter ended 30 September 2018 and for the period from 1 April 2018 to 30 September 2018 respectively and net profit after tax of INR 449.76 lakhs and INR 342.53 lakhs for the quarter ended 30 September 2018 and for the period from 1 April 2018 to 30 September 2018, respectively as considered in the Statement. This unaudited financial information have been reviewed by other auditor whose report has been furnished to us and our conclusion on the unaudited consolidated financial quarterly results and the year-to-date results to the extent they have been derived from such unaudited financial information is based solely on the report of such auditors. Our opinion is not modified in respect of this matter.

**Review report** *(continued)*

5. The unaudited consolidated financial results also include the Group's share of net profit after tax of INR 1,302.83 lakhs and INR 2,766.06 lakhs for the quarter ended 30 September 2018 and for the period from 1 April 2018 to 30 September 2018 respectively as considered in the Statement, in respect of a joint venture and an associate, whose interim financial results has not been reviewed by us. As set out in Note 11 to the Statement and as represented by the Management of the Company, the amounts included herein have been based on interim financial information of the said joint venture and associate, and have not been subjected to a review. We are unable to comment on the consequential impact that may have been required had the financial information of the joint venture and associates been subject to review.
6. Based on our review conducted as above, except for the possible impact, if any, of our observations as mentioned in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with the applicable accounting standards i.e. Ind AS prescribed under Section 133 of Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

*for B S R & Associates LLP*

*Chartered Accountants*

ICAI Firm Registration Number: 116231W/ W-100024



**Sriram Mahalingam**

*Partner*

Membership No: 049642

Place: Hyderabad

Date: 29 October 2018

*Review report (continued)*

Annexure – I

The Statement includes the results of the following entities:

**Subsidiaries:**

Granules USA Inc. (USA)

Granules Pharmaceutical Inc. (USA)

Granules Europe Limited (UK)

**Associate:**

Hubei Granules-Biocause Pharmaceutical Co. Ltd. (China)

**Joint Venture:**

Granules Omnicem Private Limited (India)

Statement of Consolidated Un-Audited Results for the quarter and half-year ended September 30, 2018

SI No.	Particulars	Quarter ended			Half-year ended		Year ended
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
	<b>Income</b>						
1	Revenue from operations (Refer note 6)	58,086.68	45,323.70	39,255.97	103,410.38	77,729.70	169,184.83
2	Other income	418.14	1,474.30	683.24	1,892.44	815.72	1,084.37
3	<b>Total income (1+2)</b>	<b>58,504.82</b>	<b>46,798.00</b>	<b>39,939.21</b>	<b>105,302.82</b>	<b>78,545.42</b>	<b>170,269.10</b>
	<b>Expenses</b>						
	(a) Cost of materials consumed	34,261.66	30,105.37	21,789.19	64,367.03	41,014.57	90,290.48
	(b) Changes in inventories of work in progress and finished goods	(2,490.24)	(5,391.48)	(2,019.80)	(7,881.72)	(3,248.29)	(658.34)
	(c) Excise duty on sales	-	-	-	-	722.60	722.60
	(d) Employee benefits expense	5,459.83	5,025.47	4,225.31	10,485.30	8,129.62	16,521.21
	(e) Finance costs	759.90	654.07	1,041.00	1,413.96	1,861.84	3,305.98
	(f) Depreciation/ amortisation expense	2,652.78	2,452.82	1,859.36	5,105.60	3,619.59	7,620.20
	(g) Other expenses	10,802.39	8,324.51	7,570.19	19,126.90	15,820.23	34,466.81
	<b>Total expenses</b>	<b>51,446.32</b>	<b>41,170.76</b>	<b>34,465.25</b>	<b>92,617.07</b>	<b>67,920.16</b>	<b>152,268.94</b>
	<b>Profit before share of profit from joint venture &amp; associate, exceptional items and tax (3-4)</b>	<b>7,058.50</b>	<b>5,627.24</b>	<b>5,473.96</b>	<b>12,685.75</b>	<b>10,625.26</b>	<b>18,000.16</b>
6	Share of Profit of joint venture and associate, net of tax	1,302.83	1,463.23	486.02	2,766.05	788.44	1,598.81
7	<b>Profit before exceptional items and tax (5+6)</b>	<b>8,361.33</b>	<b>7,090.47</b>	<b>5,959.98</b>	<b>15,451.80</b>	<b>11,413.70</b>	<b>19,598.97</b>
8	Exceptional items	-	-	-	-	-	-
9	<b>Profit before tax (7-8)</b>	<b>8,361.33</b>	<b>7,090.47</b>	<b>5,959.98</b>	<b>15,451.80</b>	<b>11,413.70</b>	<b>19,598.97</b>
10	<b>Tax expense</b>						
	a) Current tax	2,257.63	2,141.46	1,908.65	4,399.09	3,637.48	6,593.71
	b) Deferred tax	77.64	(230.55)	17.68	(152.91)	62.41	(253.86)
	<b>Total tax expense</b>	<b>2,335.27</b>	<b>1,910.91</b>	<b>1,926.33</b>	<b>4,246.18</b>	<b>3,699.89</b>	<b>6,339.85</b>
11	<b>Profit for the period (9-10)</b>	<b>6,026.06</b>	<b>5,179.56</b>	<b>4,033.65</b>	<b>11,205.62</b>	<b>7,713.81</b>	<b>13,259.12</b>
12	<b>Other Comprehensive income (net of tax)</b>						
	(a) (i) items that will not be reclassified to profit or loss	-	-	-	-	-	184.39
	(ii) income tax on (i) above	-	-	-	-	-	(62.74)
	(b) (i) items that will be reclassified to profit or loss	(91.96)	447.96	(79.81)	355.99	(74.45)	(741.14)
	(ii) income tax on (i) above	1,042.76	(165.62)	-	877.14	-	722.98
	<b>Total Other Comprehensive income, net of tax</b>	<b>950.80</b>	<b>282.34</b>	<b>(79.81)</b>	<b>1,233.13</b>	<b>(74.45)</b>	<b>103.49</b>
13	<b>Total Comprehensive income for the period (11+12)</b>	<b>6,976.86</b>	<b>5,461.90</b>	<b>3,953.84</b>	<b>12,438.75</b>	<b>7,639.36</b>	<b>13,362.61</b>
14	Paid-up equity Share Capital (Face Value of Re.1/- per share)	2,541.73	2,540.93	2,537.68	2,541.73	2,537.68	2,538.38
15	Other equity						127,879.21
16	<b>Earnings per Share (Face value Re. 1/- each) (not Annualised)</b>						
	(a) Basic (in Rs.)	2.37	2.04	1.76	4.41	3.36	5.49
	(b) Diluted (in Rs.)	2.36	2.03	1.75	4.40	3.35	5.47

## Statement of Assets and Liabilities :

Rs in Lakhs

Sl.No.	Particulars	As at	
		September 30,	March 31, 2018
		Un-Audited	Audited
I	<b>ASSETS</b>		
	Non-current assets		
	a) Property, plant and equipment	70,610.13	70,079.04
	b) Capital work-in-progress	35,190.62	29,007.22
	c) Other Intangible assets	20,308.65	7,593.92
	d) Intangible assets under development	14,476.01	22,444.39
	e) Financial assets		
	i) Investments	19,331.55	15,655.87
	ii) Loans	1,055.59	1,300.88
	f) Deferred tax assets	655.87	695.12
	g) Current tax assets (net)	51.00	45.72
	h) Other non-current assets	3,738.70	2,243.94
	<b>Total non-current assets</b>	<b>165,418.12</b>	<b>149,066.10</b>
	Current assets		
	a) Inventories	38,887.47	27,994.56
	b) Financial assets		
	i) Trade receivables	67,644.85	61,707.73
	ii) Cash and cash equivalents	11,192.17	10,803.28
	iii) Bank balances other than Cash and cash equivalents above	781.54	760.34
	iv) Loans	90.94	34.67
	v) Other financial assets	83.09	143.06
	c) Other current assets	10,915.18	13,879.24
	<b>Total current assets</b>	<b>129,595.24</b>	<b>115,322.88</b>
	<b>TOTAL ASSETS</b>	<b>295,013.36</b>	<b>264,388.98</b>
II	<b>EQUITY AND LIABILITIES</b>		
	Equity		
	a) Equity share capital	2,541.73	2,538.38
	b) Other equity	138,961.73	127,879.21
	<b>Total equity</b>	<b>141,503.46</b>	<b>130,417.59</b>
	Liabilities		
	Non-current liabilities		
	a) Financial liabilities		
	i) Borrowings	57,118.16	43,313.02
	ii) Other financial liabilities	208.42	-
	b) Provisions	1,086.86	770.05
	c) Deferred tax liabilities (net)	4,292.55	5,430.88
	<b>Total non-current liabilities</b>	<b>62,705.99</b>	<b>49,513.95</b>
	Current liabilities		
	a) Financial liabilities		
	i) Borrowings	52,664.39	52,509.95
	ii) Trade payables	29,875.28	25,218.47
	iii) Other financial liabilities	5,724.06	5,000.06
	b) Other current liabilities	1,557.34	866.64
	c) Provisions	267.13	267.13
	d) Current tax liabilities (net)	715.71	595.19
	<b>Total current liabilities</b>	<b>90,803.91</b>	<b>84,457.44</b>
	<b>Total liabilities</b>	<b>153,509.90</b>	<b>133,971.39</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>295,013.36</b>	<b>264,388.98</b>

- The above unaudited financial results for the quarter and half-year ended September 30, 2018 have been reviewed by the Audit Committee of the Board on October 29, 2018 and approved by the Board of Directors at their meeting held on October 29, 2018.
- The consolidated unaudited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and half-year ended September 30, 2018.
- The subsidiaries, joint venture and associate companies considered for the consolidated financial statements as on September 30, 2018 are Granules USA Inc., Granules Pharmaceuticals Inc., Granules Europe Limited (together known as "Subsidiaries") and Hubei Granules Biocause Pharmaceutical Co. Ltd. (known as "associate") and Granules Omnichem Pvt Ltd (known as "joint venture").
- Ind AS 115 "Revenue from Contract with Customers" is mandatory for reporting periods beginning on or after April 1, 2018 and replaces the existing revenue recognition requirements. Based on management assessment, the adoption of the standard did not have any material impact to the financial results of the company.
- Post implementation of Goods and Service Tax ("GST") with effect from 1 July 2017, revenue from operations is disclosed net of GST. For the periods prior to July 01, 2017, the excise duty amount was recorded as part of revenue with a corresponding amount recorded as expense. Accordingly, revenue from operations for the half-year ended September 30, 2018 are not comparable with those of the previous period presented. Following additional information is being provided to facilitate such comparison :

Particulars	Quarter ended			Half-year ended		Year ended
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
i) Revenue from Operations	58,086.68	45,323.70	39,255.97	103,410.38	77,729.70	169,184.83
ii) Excise duty	-	-	-	-	722.60	722.60
iii) Revenue from Operations (i-ii)	58,086.68	45,323.70	39,255.97	103,410.38	77,007.10	168,462.23

- As per regulation 33 of the Listing Regulations, the Company has opted to publish only consolidated financial results. The standalone financial results are available for perusal at Company's website viz., www.granulesindia.com and websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- During the quarter, the Company has allotted 80,000 equity shares of Re.1/- each, fully paid up on exercise of options by employees in accordance with the Company's Employee Stock Option Scheme(s).
- The Board of Directors at their meeting held on October 29, 2018 has declared second interim dividend of 25 paise per equity share of Re.1/- each.
- The financial results include the Company's share of profits (net) aggregating of Rs. 1,302.83 lakhs for quarter ended September 30, 2018 and half-year ended Rs. 2,766.06 lakhs from joint venture in which the Company is Co-venturer and an associate. These financial results are based on the management certified financial information of the joint venture and an associate. As the joint venture and an associate do not present reviewed financial results on a quarterly basis, amount included therein have not been subject to review by the Statutory Auditors of the respective joint venture and an associate.
- Standalone Results for the quarter ended are as under -

Particulars	Quarter ended			Half-year ended		Year ended
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
Revenue from Operations	51,594.32	44,033.91	37,352.75	95,628.23	76,788.96	165,386.92
Profit Before Tax	6,161.60	5,927.09	5,357.09	12,088.69	10,646.47	20,845.29
Profit After Tax	4,082.04	3,956.92	3,563.63	8,038.96	7,114.39	13,916.19

Place : Hyderabad  
Date : October 29, 2018

for and on behalf of the Board  
  
Hyderabad  
Kristina Prasad Chigurupati  
Chairman and Managing Director

# B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City  
Orwell, 6th Floor, Unit-3  
Sy. No. 83/1, Plot No. 2, Raidurg  
Hyderabad-500081, India

Telephone : +91 40 7182 2000  
Fax : +91 40 7182 2399

## Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results pursuant to the Regulation 33 of the Listing Regulations

To

**The Board of Directors of Granules India Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results ('Statement') of Granules India Limited ('the Company') for the quarter ended 30 September 2018 and the year-to-date results for the period from 1 April 2018 to 30 September 2018 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement, based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" specified under section 143 (10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the applicable accounting standards i.e. Ind AS prescribed under Section 133 of Companies Act, 2013 and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 116231W/ W-100024

**Sriram Mahalingam**

Partner

Membership No: 049642

Place: Hyderabad

Date: 29 October 2018

Statement of Standalone Un-Audited Results for the quarter and half-year ended September 30, 2018

SI No.	Particulars	Quarter ended			Half-year ended		Year ended
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
	<b>Income</b>						
1	Revenue from operations (Refer note 5)	51,594.32	44,033.91	37,352.75	95,628.23	76,788.96	165,386.92
2	Other income	345.74	1,801.81	1,010.95	2,147.55	1,405.82	2,377.13
3	<b>Total income (1+2)</b>	<b>51,940.06</b>	<b>45,835.72</b>	<b>38,363.70</b>	<b>97,775.78</b>	<b>78,194.78</b>	<b>167,764.05</b>
	<b>Expenses</b>						
	(a) Cost of materials consumed	33,706.37	29,440.73	20,510.60	63,147.10	39,540.62	89,020.17
	(b) Changes in inventories of work in progress and finished goods	(3,675.05)	(4,098.09)	(1,156.58)	(7,773.14)	85.40	1,289.37
	(c) Excise duty on sales	-	-	-	-	722.60	722.60
	(d) Employee benefits expense	4,140.64	4,144.79	3,743.39	8,285.43	7,173.48	14,792.40
	(e) Finance costs	759.14	652.35	1,039.86	1,411.49	1,858.09	3,292.70
	(f) Depreciation/amortisation expense	2,264.72	2,187.09	1,851.46	4,451.81	3,603.87	7,591.64
	(g) Other expenses	8,582.64	7,581.76	7,017.88	16,164.40	14,564.25	30,209.88
	<b>Total expenses</b>	<b>45,778.46</b>	<b>39,908.63</b>	<b>33,006.61</b>	<b>85,687.09</b>	<b>67,548.31</b>	<b>146,918.76</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>6,161.60</b>	<b>5,927.09</b>	<b>5,357.09</b>	<b>12,088.69</b>	<b>10,646.47</b>	<b>20,845.29</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit before tax (5-6)</b>	<b>6,161.60</b>	<b>5,927.09</b>	<b>5,357.09</b>	<b>12,088.69</b>	<b>10,646.47</b>	<b>20,845.29</b>
8	<b>Tax expense</b>						
	a) Current tax	2,257.63	2,141.46	1,729.42	4,399.09	3,409.86	6,389.75
	b) Deferred tax	(178.07)	(171.29)	64.04	(349.36)	122.22	539.35
	<b>Total tax expense</b>	<b>2,079.56</b>	<b>1,970.17</b>	<b>1,793.46</b>	<b>4,049.73</b>	<b>3,532.08</b>	<b>6,929.10</b>
9	<b>Profit for the period (7-8)</b>	<b>4,082.04</b>	<b>3,956.92</b>	<b>3,563.63</b>	<b>8,038.96</b>	<b>7,114.39</b>	<b>13,916.19</b>
10	<b>Other Comprehensive income (net of tax)</b>						
	(a) (i) items that will not be reclassified to profit or loss	-	-	-	-	-	181.30
	(ii) income tax on (i) above	-	-	-	-	-	(62.74)
	(b) (i) items that will be reclassified to profit or loss	(2,984.09)	473.96	-	(2,510.13)	-	(2,068.98)
	(ii) income tax on (i) above	1,042.76	(165.62)	-	877.14	-	722.98
	<b>Total Other Comprehensive income, net of tax</b>	<b>(1,941.33)</b>	<b>308.34</b>	<b>-</b>	<b>(1,632.99)</b>	<b>-</b>	<b>(1,227.44)</b>
11	<b>Total Comprehensive income for the period (9+10)</b>	<b>2,140.71</b>	<b>4,265.26</b>	<b>3,563.63</b>	<b>6,405.97</b>	<b>7,114.39</b>	<b>12,688.75</b>
12	Paid-up equity Share Capital (Face Value of Re.1/- per share)	2,541.73	2,540.93	2,537.68	2,541.73	2,537.68	2,538.38
13	Other equity						125,281.43
14	<b>Earnings per Share (Face value Re. 1/- each) (not Annualised)</b>						
	(a) Basic (in Rs.)	1.61	1.56	1.55	3.17	3.10	5.76
	(b) Diluted (in Rs.)	1.60	1.55	1.55	3.16	3.09	5.74



## Statement of Assets and Liabilities :

Rs in lakhs

Sl. No.	Particulars	As at	
		September 30, Un-Audited	March 31, 2018 Audited
I	<b>ASSETS</b>		
	<b>Non-current assets</b>		
	a) Property, plant and equipment	58,309.45	58,854.11
	b) Capital work-in-progress	33,064.12	27,103.91
	c) Other Intangible assets	6,893.98	7,161.36
	d) Intangible assets under development	1,839.54	1,498.71
	e) Financial assets		
	i) Investments	50,646.30	7,511.58
	ii) Loans	5,700.90	41,873.88
	f) Other non-current assets	2,698.86	2,026.25
	<b>Total non-current assets</b>	<b>159,153.15</b>	<b>146,029.80</b>
	<b>Current assets</b>		
	a) Inventories	33,280.79	22,735.65
	b) Financial assets		
	i) Trade receivables	70,157.52	68,173.67
	ii) Cash and cash equivalents	8,821.70	8,980.94
	iii) Bank balances other than Cash and cash equivalents above	781.54	760.34
	iv) Loans	77.32	20.36
	v) Other financial assets	33.50	36.55
	c) Other current assets	10,501.93	13,808.73
	<b>Total current assets</b>	<b>123,654.30</b>	<b>114,516.24</b>
	<b>TOTAL ASSETS</b>	<b>282,807.45</b>	<b>260,546.04</b>
II	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	a) Equity share capital	2,541.73	2,538.38
	b) Other equity	130,331.19	125,281.43
	<b>Total equity</b>	<b>132,872.92</b>	<b>127,819.81</b>
	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	a) Financial liabilities		
	i) Borrowings	57,118.16	43,313.02
	b) Provisions	1,086.86	770.05
	c) Deferred tax liabilities (net)	5,055.29	6,281.80
	<b>Total non-current liabilities</b>	<b>63,260.31</b>	<b>50,364.87</b>
	<b>Current liabilities</b>		
	a) Financial liabilities		
	i) Borrowings	52,664.39	52,509.95
	ii) Trade payables	27,000.20	23,837.87
	iii) Other financial liabilities	5,290.84	4,583.84
	b) Other current liabilities	645.27	588.75
	c) Provisions	267.13	267.13
	d) Current tax liabilities (net)	806.39	573.82
	<b>Total current liabilities</b>	<b>86,674.22</b>	<b>82,361.36</b>
	<b>Total liabilities</b>	<b>149,934.53</b>	<b>132,726.23</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>282,807.45</b>	<b>260,546.04</b>

- The above unaudited financial results for the quarter and half year ended September 30, 2018 have been reviewed by the Audit Committee of the Board on October 29, 2018 and approved by the Board of Directors at their meeting held on October 29, 2018.
- The standalone unaudited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2018.
- Ind AS 115 "Revenue from Contract with Customers" is mandatory for reporting periods beginning on or after April 1, 2018 and replaces the existing revenue recognition requirements. Based on management assessment, the adoption of the standard did not have any material impact to the financial results of the company.
- Post implementation of Goods and Service Tax ("GST") with effect from July 01, 2017, revenue from operations is disclosed net of GST. For the periods prior to July 01, 2017, the excise duty amount was recorded as part of revenue with a corresponding amount recorded as expense. Accordingly, revenue from operations for the half year ended September 30, 2018 are not comparable with those of the previous period presented. Following additional information is being provided to facilitate such comparison :

Particulars	Quarter ended			Half-year ended		Year ended
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
i) Revenue from Operations	51,594.32	44,033.91	37,352.75	95,628.23	76,788.96	165,386.92
ii) Excise duty	-	-	-	-	722.60	722.60
iii) Revenue from Operations (i-ii)	51,594.32	44,033.91	37,352.75	95,628.23	76,066.36	164,664.32

- As per regulation 33 of the Listing Regulations, the Company has opted to publish only consolidated financial results. The standalone financial results are available for perusal at Company's website viz., [www.granulesindia.com](http://www.granulesindia.com) and websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
- The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- During the quarter, the Company has allotted 80,000 equity shares of Re.1/- each, fully paid up on exercise of options by employees in accordance with the Company's Employee Stock Option Scheme(s).
- During the quarter ended September 30, 2018, the Company, based on the approval of the Board, has partially converted the loan given to Granules Pharmaceutical Inc. (Wholly-owned subsidiary) into equity shares, to the extent of Rs 43,134.72 lakhs, regulatory reporting in respect of which is initiated.
- The Board of Directors at their meeting held on October 29, 2018 has declared second interim dividend of 25 paise per equity share of Re.1/- each.

for and on behalf of the Board



Krishna Prasad Chigurupati  
Chairman and Managing Director

Place : Hyderabad  
Date : October 29, 2018



**Press Release**

**Granules India's Net Profit grew by 49% to INR 60 Cr.**

Hyderabad, October 29, 2018: Granules India Ltd., a growing pharmaceutical manufacturing company, announced today its financial results for the second quarter ended 30th September 2018.

CONSOLIDATED FINANCIALS	Q2 FY'19	Y-o-Y Growth
TOTAL INCOME	INR 585 Crs.	46%
EBITDA	INR 105 Crs.	25%
PAT	INR 60 Crs.	49%

The Company's Board of Directors has approved second interim dividend of 25 paise per share of face value of Rs. 1 each.

The Board has appointed Mr. Arun Sawhney as an Additional Director, categorized as Independent. A brief profile of Mr. Sawhney is enclosed in the press release.

*"We are pleased with the strong Revenue growth reported in this quarter combined with a significant increase in our Profit over the corresponding quarter of the previous year which reflects our relentless execution and operational excellence. The growth is attributed to increased sales from API and formulation business. The adverse impact on our gross margin owing to the spike in raw material prices continues, but we have been able to successfully pass on the incremental cost to our customers, though with a small lag. We hope to maintain this momentum of growth and fiscal prudence in subsequent quarters.*

*In addition, this quarter was very special for Granules in terms of achieving a key milestone. We have successfully launched the generic version of Methocarbamol and Metformin XR in the United States under our own label without any marketing partner. We would like to inform you that we have recently concluded US FDA audit at our Virginia facility with two observations. This was a five-day 'prior approval inspection' which is an integral part of the ANDA approval process for the products filed by GPI", said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited.*



**Brief profile of Mr. Arun Sawhney**

Mr. Arun Sawhney holds Bachelor Degree in commerce from the University of Mumbai and Post Graduate Diploma in Management from IMI. Mr. Sawhney has almost four decades of experience in diverse industries including Software, Rubber, Chemicals, Generic & OTC Pharmaceuticals, where he established new norms of business as well as repeatedly challenged the status quo.

In the last position as CEO and Managing Director of Ranbaxy Laboratories Limited, Mr. Sawhney successfully led one of the largest mergers in Indian Corporate history. In the past he was also associated with Max-Gb Limited and Dr. Reddy's Laboratories Ltd in various capacities.

Mr. Sawhney was also a founder member of Indian Pharmaceutical Export Promotion Council (Pharmexcil) and was Chairman of Pharmaceutical Committee of the Confederation of Indian Industries (CII) during the period 2012-2014.

Mr. Sawhney is currently engaged with leading companies in India and Europe on coaching their Senior Executives. He is also a visiting faculty at IIM-Lucknow for subjects of Leadership Behaviour.



About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K. The Company has 8 manufacturing facilities out of which 6 are located in India, 1 in China and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

**Contacts:**

Sumanta Bajpayee  
Corporate Finance & Investor Relations  
040-30663572  
sumanta.bajpayee@granulesindia.com

Chaitanya Tummala  
Company Secretary  
040-30663614  
chaitanya.tummala@granulesindia.com

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*